LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinoma

Libin Wang; Feng Wang; Li Na; Jingjing Yu; Liya Huang; Zhi-Qiang Meng; Zhen Chen; Hao Chen; Liu-Lu Ming; Yong-Qiang Hua

doi:10.3233/CBM-181182

LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinoma

Cancer Biomark. 2018;22(1):169-174. doi: 10.3233/CBM-181182.

Authors

Libin Wang^{1

1}, Feng Wang^{2

1}, Li Na³, Jingjing Yu¹, Liya Huang⁴, Zhi-Qiang Meng^{5

6}, Zhen Chen^{5

6}, Hao Chen^{5

6}, Liu-Lu Ming^{5

6}, Yong-Qiang Hua^{5

6}

Affiliations

¹ Department of Beijing National Biochip Research Center Sub-Center in Ningxia, The General Hospital of Ningxia Medical University, Yinchuan 750001, Ningxia, China.
² Department of Hepatobiliary Surgery, The General Hospital of Ningxia Medical University, Yinchuan 750001, Ningxia, China.
³ Department of Biobank, The General Hospital of Ningxia Medical University, Yinchuan 750001, Ningxia, China.
⁴ Department of Gastroenterology, The General Hospital of Ningxia Medical University, Yinchuan 750001, Ningxia, China.
⁵ Minimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
⁶ Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

PMID: 29526843
DOI: 10.3233/CBM-181182

Abstract

Background: Recent study revealed that abnormal long noncoding RNAs (lncRNAs) expression are association with chemotherapy resistance of pancreatic ductal adenocarcinoma (PDAC).

Objective: The present study was aimed to investigate the effects of lncRNA AB209630 expression for gemcitabine resistance in PDAC cells.

Methods: In the study, increased expression of lncRNA AB209630 could suppress cell proliferation and cell colony formation ability in gemcitabine resistance cells of PDAC. Furthermore, western blot results demonstrated that upregulation of lncRNA AB209630 suppressed the PI3K/AKT signaling pathway in gemcitabine resistance cells. Besides, we found that lncRNA AB209630 expression was dramatically downregulated in PDAC tissues compared to adjacent normal tissues. Lower PDAC expression predicted a poor prognosis in PDAC patients.

Conclusions: Thus, these results indicated that lncRNA AB209630 may be a potential target of PDAC.

Keywords: AB209630; PI3K/AKT signaling; Pancreatic ductal adenocarcinoma; gemcitabine resistance; long non-coding RNA.

MeSH terms

Antimetabolites, Antineoplastic / pharmacology*
Carcinoma, Pancreatic Ductal / drug therapy
Carcinoma, Pancreatic Ductal / genetics*
Carcinoma, Pancreatic Ductal / pathology
Cell Line, Tumor
Cell Proliferation / drug effects
Deoxycytidine / analogs & derivatives*
Deoxycytidine / pharmacology
Down-Regulation
Drug Resistance, Neoplasm
Female
Gemcitabine
Humans
Male
Phosphatidylinositol 3-Kinases / metabolism*
Phosphoinositide-3 Kinase Inhibitors
Prognosis
Proto-Oncogene Proteins c-akt / antagonists & inhibitors
Proto-Oncogene Proteins c-akt / metabolism*
RNA, Long Noncoding / biosynthesis
RNA, Long Noncoding / genetics
Up-Regulation

Substances

Antimetabolites, Antineoplastic
Phosphoinositide-3 Kinase Inhibitors
RNA, Long Noncoding
long non-coding RNA AB209630, human
Deoxycytidine
Proto-Oncogene Proteins c-akt
Gemcitabine